This connection is particularly intriguing given the evidence that the R-enantiomer of ketorolac, a widely available drug, exhibits potent inhibition of Rac1 activity and growth of ovarian cancer cells, and peri-operative administration has been associated with a survival benefit in previous retrospective studies of patients with ovarian cancer [97,98,99]. Here, RAC1 is linked to ovarian cancer.